(0.12%) 5 303.27 points
(0.34%) 40 004 points
(-0.07%) 16 686 points
(-0.07%) $80.00
(0.46%) $2.64
(0.10%) $2 419.80
(1.65%) $31.78
(0.43%) $1 094.70
(-0.09%) $0.919
(-0.18%) $10.68
(-0.17%) $0.788
(0.19%) $91.05
Live Chart Being Loaded With Signals
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally...
Stats | |
---|---|
Šios dienos apimtis | 4 121.00 |
Vidutinė apimtis | 10 901.00 |
Rinkos kapitalizacija | 21.43M |
EPS | $0 ( 2024-05-14 ) |
Kita pelno data | ( $0 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.43 |
ATR14 | $0.0170 (1.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Krogulski Kenneth | Buy | 5 000 | Common Stock |
2024-03-25 | Jones James | Buy | 1 000 | Common Stock |
2024-03-25 | Galante Joseph C | Buy | 1 000 | Common Stock |
2024-03-25 | Young Caroline | Buy | 1 000 | Common Stock |
2024-03-25 | Brown Martin S Jr | Buy | 1 000 | Common Stock |
INSIDER POWER |
---|
64.38 |
Last 100 transactions |
Buy: 135 322 | Sell: 29 102 |
Cumberland Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
DMRC | 0.907 |
GTEC | 0.894 |
LUNA | 0.893 |
NEPH | 0.893 |
AZ | 0.891 |
DLHC | 0.888 |
TELA | 0.888 |
ZS | 0.886 |
TACT | 0.883 |
MTEM | 0.881 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
IGLD | -0.878 |
ROOT | -0.873 |
STAA | -0.868 |
KNTK | -0.866 |
VTVT | -0.864 |
KALU | -0.863 |
VITL | -0.862 |
PPTA | -0.861 |
TIGO | -0.861 |
BNR | -0.86 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Cumberland Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $39.55M |
Bruto pelnas: | $28.55M (72.18 %) |
EPS: | $-0.440 |
FY | 2023 |
Pajamos: | $39.55M |
Bruto pelnas: | $28.55M (72.18 %) |
EPS: | $-0.440 |
FY | 2022 |
Pajamos: | $42.01M |
Bruto pelnas: | $32.89M (78.29 %) |
EPS: | $-0.390 |
FY | 2021 |
Pajamos: | $35.99M |
Bruto pelnas: | $27.17M (75.51 %) |
EPS: | $-0.240 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cumberland
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.